Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRITON-CM: Nucresiran in ATTR Amyloidosis with Cardiomyopathy
jRCT2011250038Phase 3Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Oct 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 3, randomised, double-blind trial in transthyretin amyloidosis (ATTR) comparing Nucresiran arm with Placebo arm (2 arms). Primary endpoint: Composite of all-cause mortality and recurrent cardiovascular events. Started Oct 2025; status: recruiting.
02
Drugs
nucresiran
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on jRCT2011250038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250038.